Phase II study of bevacizumab (Avastin) and erlotinib (Tarceva) in previously treated malignant mesothelioma.

Trial Profile

Phase II study of bevacizumab (Avastin) and erlotinib (Tarceva) in previously treated malignant mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Dec 2011 Additional lead trial investigator (Pasi A Janne) identified as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Additional lead trial centres and lead investigator identified as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top